製药用低温阀市场机会、成长驱动因素、产业趋势分析及2025-2034年预测

2024 年全球製药用低温阀市场价值为 5.773 亿美元，预计到 2034 年将以 7.5% 的复合年增长率增长至 11.9 亿美元。

製药和生物技术应用领域对液态氮、氩气和氧气等特殊气体的需求不断增长，推动了市场发展。这些气体在药物保存、疫苗储存和实验室研究等领域至关重要，而这些领域都需要超低温环境。低温阀门是关键零件，可确保在无菌高压条件下精确控制并安全输送这些气体。低温阀门的使用有助于製药公司遵守国际防洩漏、材料纯度和卫生标准。随着製药公司越来越多地使用低温系统来支持生物製药生产和冷链储存，对先进低温阀门的需求持续成长。对温度敏感的药物和生物製剂产量不断提高，为阀门製造商创造了新的机会，他们可以提供满足严格安全性和性能标准的专用解决方案。总而言之，低温技术在现代製药营运中的应用，凸显了高效能优质低温阀门在全球范围内的重要性。

由于其结构紧凑、成本效益高，且能够承受高压高温环境，隔膜阀在2024年占据了26.1%的市场份额。随着製药业对水基础设施投资的增加，隔膜阀的作用日益凸显，它们在水净化、处理和无菌系统管理等流程中发挥越来越重要的作用。隔膜阀在这些系统中的日益普及，凸显了它们在维持製药生产设施清洁、可控和可靠运作方面的重要作用。

到2024年，直销通路市占率将达到65%。製造商与製药公司直接对接，能够确保高品质的产品供应，并促进更牢固的业务关係。透过减少中间环节，企业可以降低整体采购成本，并提供高效的售后服务，这在设备可靠性和温度控制精度至关重要的行业中是一项关键优势。此外，这种直接模式还允许製造商根据客户的具体要求定制解决方案，从而更好地响应製药应用日益增长的、对性能和可追溯性要求极高的市场需求。

2024年，美国製药用低温阀市占率达到78.8%，这反映了其强大的製药生产基础和在研发方面的巨额投入。联邦政府在製药研发方面的支出超过700亿美元，大大促进了低温系统的技术进步和创新。对温度敏感药物可靠储存和运输需求的不断增长，推动了低温阀在生产和物流网路中的应用。此外，美国食品药物管理局（FDA）对品质保证的持续重视以及生物製药基础设施的现代化，也支持了先进低温处理系统的广泛应用，使美国成为重要的市场中心。

全球製药用低温阀门市场的主要参与者包括Flowserve、Baker Hughes、Velan、Parker Hannifin、Kitz、Swagelok、Herose、Powell Valves、Trimteck、Rego、PK Valve and Engineering、Crane Company、Bray International、Microfinish和Emerson。这些公司采取的关键策略着重于加强技术创新、策略合作和全球扩张。主要企业优先投资研发，以开发具有更高密封性能、更强灭菌相容性和更耐极端温度的阀门。许多公司正与製药厂商建立合作关係，共同开发符合业界特定标准的客製化低温解决方案。扩大生产能力和加强新兴市场的本地分销网络也是提高产品可近性的关键步骤。

目录

第一章：方法论与范围

第二章：执行概要

第三章：行业洞察

• 产业生态系分析
  • 供应商格局
  • 利润率
  • 每个阶段的价值增加
  • 影响价值链的因素
• 产业影响因素
  • 成长驱动因素
    • 对特种药品的需求不断增长
    • 扩建空气分离装置（ASU）
    • 注重营运安全和效率
  • 产业陷阱与挑战
    • 合规和认证成本高昂
    • 材料相容性问题
  • 机会
    • 新兴市场和生物技术中心
    • 自动化和智慧阀门技术
• 成长潜力分析
• 未来市场趋势
• 技术与创新格局
  • 当前技术趋势
  • 新兴技术
• 价格趋势
  • 按地区
  • 按阀门类型
• 监管环境
  • 标准和合规要求
  • 区域监理框架
  • 认证标准
• 贸易统计（HS编码- 84818090）
  • 主要进口国
  • 主要出口国
• 差距分析
• 风险评估与缓解
• 波特的分析
• PESTEL 分析

第四章：竞争格局

• 介绍
• 公司市占率分析
  • 按地区
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 关键进展
  • 併购
  • 合作伙伴关係与合作
  • 新产品发布
  • 扩张计划

第五章：市场估算与预测：依阀门类型划分，2021-2034年

• 主要趋势
• 球阀
• 隔膜阀
• 球阀
• 止回阀
• 其他（洩压阀、安全阀、电磁阀等）

第六章：市场估算与预测：依阀门尺寸划分，2021-2034年

• 主要趋势
• 小于1英寸
• 介于 1 到 4 英吋之间
• 介于 4 到 8 英吋之间
• 超过 8 英寸

第七章：市场估计与预测：依应用领域划分，2021-2034年

• 主要趋势
• 生物加工和生物製药
• 疫苗储存和冷链
• 细胞和基因治疗
• 冷冻干燥
• 其他（医用气体、冷冻保存等）

第八章：市场估算与预测：依配销通路划分，2021-2034年

• 主要趋势
• 直接的
• 间接

第九章：市场估计与预测：依地区划分，2021-2034年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• MEA
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第十章：公司简介

• Baker Hughes
• Bray International
• CP Valves (Hammer brand)
• Crane Company
• Cryofab, Inc.
• Emerson
• Flowserve
• Herose
• Kitz
• Microfinish
• Parker Hannifin
• PK Valve and Engineering
• Steriflow Valve
• Swagelok
• Velan

The Global Cryogenic Valve for Pharmaceutical Market was valued at USD 577.3 million in 2024 and is estimated to grow at a CAGR of 7.5% to reach USD 1.19 Billion by 2034.

Increasing demand for specialty gases such as liquid nitrogen, argon, and oxygen across pharmaceutical and biotechnology applications is driving market growth. These gases are essential in areas such as drug preservation, vaccine storage, and laboratory research, all of which require ultra-low temperature environments. Cryogenic valves are critical components that ensure precise control and secure transfer of these gases under sterile and high-pressure conditions. Their use supports compliance with international standards for leak prevention, material purity, and hygiene in pharmaceutical operations. As pharmaceutical companies increase the use of cryogenic systems to support biopharmaceutical manufacturing and cold-chain storage, demand for advanced cryogenic valves continues to expand. The rising production of temperature-sensitive medicines and biologics is creating new opportunities for valve manufacturers offering specialized solutions that meet strict safety and performance criteria. Overall, the integration of cryogenic technology into modern pharmaceutical operations is reinforcing the importance of efficient and high-quality cryogenic valves worldwide.

The diaphragm valves segment held 26.1% share in 2024, owing to their compact design, cost-effectiveness, and capability to withstand high-pressure and high-temperature applications. Their role has become even more significant as investment in water infrastructure has increased across the pharmaceutical sector, supporting processes such as water purification, treatment, and sterile system management. The growing application of diaphragm valves in such systems underscores their essential function in maintaining clean, controlled, and reliable operations within pharmaceutical production facilities.

The direct sales channel segment held a 65% share in 2024. Direct engagement between manufacturers and pharmaceutical companies ensures high-quality product supply and fosters stronger business relationships. By minimizing intermediaries, companies reduce overall procurement costs and provide efficient after-sales services, a key advantage in industries where equipment reliability and temperature control precision are vital. The direct approach also allows manufacturers to tailor solutions to client specifications, improving responsiveness to the growing needs of pharmaceutical applications that demand stringent performance and traceability.

United States Cryogenic Valve for Pharmaceutical Market held a 78.8% share in 2024, reflecting its strong pharmaceutical production base and substantial investments in research and development. Federal spending on pharmaceutical R&D exceeding USD 70 Billion has significantly contributed to technological advancement and innovation in cryogenic systems. The increasing requirement for reliable storage and transport of temperature-sensitive drugs has fueled the adoption of cryogenic valves across manufacturing and logistics networks. Furthermore, the Food and Drug Administration's continued emphasis on quality assurance and modernized biopharmaceutical infrastructure supports the widespread implementation of advanced cryogenic handling systems, positioning the U.S. as a major market hub.

Leading players in the Global Cryogenic Valve for Pharmaceutical Market include Flowserve, Baker Hughes, Velan, Parker Hannifin, Kitz, Swagelok, Herose, Powell Valves, Trimteck, Rego, PK Valve and Engineering, Crane Company, Bray International, Microfinish, and Emerson. Key strategies employed by companies in the Cryogenic Valve For Pharmaceutical Market focus on enhancing technological innovation, strategic collaborations, and global expansion. Major firms are prioritizing R&D investments to develop valves with improved sealing performance, sterilization compatibility, and durability under extreme temperatures. Many companies are forming partnerships with pharmaceutical manufacturers to co-develop customized cryogenic solutions that meet industry-specific standards. Expanding manufacturing capacities and strengthening local distribution networks in emerging markets are also vital steps to improve accessibility.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional
  • 2.2.2 Valve type
  • 2.2.3 Valve size
  • 2.2.4 Application
  • 2.2.5 Distribution channel
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Profit margin
  • 3.1.3 Value addition at each stage
  • 3.1.4 Factor affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising demand for specialty pharmaceuticals
    • 3.2.1.2 Expansion of air separation units (ASUs)
    • 3.2.1.3 Focus on operational safety and efficiency
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of compliance and certification
    • 3.2.2.2 Material compatibility issues
  • 3.2.3 Opportunities
    • 3.2.3.1 Emerging markets and biotech hubs
    • 3.2.3.2 Automation and smart valve technologies
• 3.3 Growth potential analysis
• 3.4 Future market trends
• 3.5 Technology and innovation landscape
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Price trends
  • 3.6.1 By Region
  • 3.6.2 By Valve type
• 3.7 Regulatory landscape
  • 3.7.1 Standards and compliance requirements
  • 3.7.2 Regional regulatory frameworks
  • 3.7.3 Certification standards
• 3.8 Trade statistics (HS code- 84818090)
  • 3.8.1 Major importing countries
  • 3.8.2 Major exporting countries
• 3.9 Gap analysis
• 3.10 Risk assessment and mitigation
• 3.11 Porter's analysis
• 3.12 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 By region
    • 4.2.1.1 North America
    • 4.2.1.2 Europe
    • 4.2.1.3 Asia Pacific
    • 4.2.1.4 Latin America
    • 4.2.1.5 Middle East and Africa
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers & acquisitions
  • 4.6.2 Partnerships & collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates & Forecast, By Valve type, 2021-2034 (USD Million) (Thousand Units)

• 5.1 Key trends
• 5.2 Ball valve
• 5.3 Diaphragm valves
• 5.4 Globe valve
• 5.5 Check valve
• 5.6 Others (relief, safety, solenoid valve etc.)

Chapter 6 Market Estimates & Forecast, By Valve size, 2021-2034 (USD Million) (Thousand Units)

• 6.1 Key trends
• 6.2 Less than 1 inch
• 6.3 Between 1 to 4 inches
• 6.4 Between 4 to 8 inches
• 6.5 More than 8 inches

Chapter 7 Market Estimates & Forecast, By Application, 2021-2034 (USD Million) (Thousand Units)

• 7.1 Key trends
• 7.2 Bioprocessing and biopharmaceutical
• 7.3 Vaccine storage and cold chain
• 7.4 Cell and gene therapy
• 7.5 Freeze drying
• 7.6 Others (medical gas, cryopreservation etc.)

Chapter 8 Market Estimates & Forecast, By Distribution Channel, 2021-2034 (USD Million) (Thousand Units)

• 8.1 Key trends
• 8.2 Direct
• 8.3 Indirect

Chapter 9 Market Estimates & Forecast, By Region, 2021-2034 (USD Million) (Thousand Units)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 MEA
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Baker Hughes
• 10.2 Bray International
• 10.3 C.P. Valves (Hammer brand)
• 10.4 Crane Company
• 10.5 Cryofab, Inc.
• 10.6 Emerson
• 10.7 Flowserve
• 10.8 Herose
• 10.9 Kitz
• 10.10 Microfinish
• 10.11 Parker Hannifin
• 10.12 PK Valve and Engineering
• 10.13 Steriflow Valve
• 10.14 Swagelok
• 10.15 Velan